EGFR and non-small cell lung carcinoma: Initially, when treating patients carrying EGFR‐mutated NSCLC with intermediate or high PD‐L1 expression, it is important to assess osimertinib efficacy at brief intervals owing to the potential for early resistance to osimertinib.